Bradley Joblin from Armstrong Clinical has been invited to be the guest speaker at the AGM of HSP Research Foundation. Hereditary Spastic Paraplegia (HSP) is a rare degenerative neurological disorder without any current treatment options. Through innovative stem cell technologies, the HSP research team, including Australian of the Year Prof. Alan Mackay-Sim, has discovered a potential new therapy for HSP. Armstrong Clinical has been supporting the HSP Research Foundation in their efforts to take this potential disease modifying therapy to patients.
Comment from Brad “Armstrong Clinical has been supporting the HSP research Foundation for the last year, helping with pre-clinical evidence generation requirement, predictive dose modeling, designing their phase 1/2a study, and the on-going path to market. I look forward to being part of the AGM and discussing with all stakeholders, patients, clinicians, and interested parties, the path for approval of this therapy and the planned phase 1/2a clinical study”. For more information on the HSP research foundation click here https://hspersunite.org.au.